Observe Medical ASA: Registration of new share capital

Oslo, 9 July

Reference is made to the announcement by Observe Medical ASA (the "Company" or"Observe Medical", OSE ticker "OBSVR") on 3 July 2025, regarding theresolutionby the extraordinary the general meeting to increase the Company's sharecapitalin connection with a private placement (the "Private Placement") by theissuanceof (i) 56,890,000 new shares to investors in the Private Placement and (ii)10,000,000 new shares to Navamedic ASA in connection with a loan conversion(together the "Offer Shares").

The share capital increase pertaining to the Offer Shares, has today beenregistered with the Norwegian Register of Business Enterprises (Nw.Foretaksregisteret).

The Company's share capital is NOK 38,702,333.04, divided into 92,148,412shares, each with a nominal value of NOK 0.42.

The Offer Shares will be registered with the Norwegian Central SecuritiesDepository Euronext Securities Oslo (the "VPS") on a separate ISIN from theexisting shares of the Company, pending approval and publication by theCompanyof a prospectus (the "Prospectus") and will thus not be tradable on EuronextExpand Oslo until the Prospectus has been approved by the FinancialSupervisoryAuthority of Norway (the "NFSA") and published by the Company, upon which theOffer Shares will be transferred to the Company's ordinary ISIN in the VPS andbe admitted to trading on Euronext Expand Oslo. The Prospectus is expected tobeapproved by the NFSA and published by the Company at the end of Q3 2025.

This information is subject to the disclosure requirements pursuant to section5-12 of the Norwegian Securities Trading Act.

For further information, please contact:

Jørgen Mann, CEO Observe MedicalMobile: +45 408 67 558E-mail: jorgen.mann@observemedical.com

Johan Fagerli, CFO Observe MedicalMobile: +47 958 12 765E-mail: johan.fagerli@observemedical.com

About Observe Medical:

Observe Medical is a Nordic medtech company that develops, markets and sellsinnovative medtech products for the global market. The Company is committed toimproving patient welfare and patient outcomes, improving clinical dataaccuracyand promoting positive health economics.

The Company seeks to drive growth by leveraging its expertise in sales andcommercialisation of its broad portfolio of medical technology products,mainlyin urine measurement and ultrasound, in combination with targeted M&A anddistribution. Observe Medical is working with a network of leadingdistributorsto provide outstanding solutions for healthcare professionals globally.

The Company is headquartered in Oslo, Norway.

Further information is available at www.observemedical.com.

https://newsweb.oslobors.no/message/650941